Les Funtleyder
Les Funtleyder
coming cut plenty possible products quite seeing start
When you start seeing these big, big products coming off patent, there's plenty for most of them to cut. It is quite possible that all of them have plenty more to cut if they want to.
body company defensive future guidance internal itself lack management performance savvy scale seemed terms
In terms of body language, management seemed a little more defensive to us than usual. Moreover, we find the lack of guidance from a company with the scale and savvy of Pfizer worrisome; it suggests to us that the company doesn't know itself about the future performance of its own internal operations.
certainly encourage people reserve
It certainly will encourage more people to sue. This is going to be a decade-long process. It's probably going to make Merck reserve more money.
surprise upside
That was the first upside surprise for Merck in a long time.
brighter capability future hope months novel offers points products proves
For Pfizer, it offers some hope for the future that they can get novel products to market. This proves that they have drug development capability and points to a brighter future 18 months out.
drive greater helps larger scale terms
Getting larger really does matter. Scale helps because it helps drive greater discounts. The more enrollees you have, the better off you are in terms of costs.
companies list relatively
The list is relatively short. There aren't that many companies who could take it.